Zai Lab, Boehringer Ingelheim team up on DLL3 combo trial in lung cancer

PUBT·04/15/2026 12:43:27

Listen to the news

Zai Lab entered clinical collaboration with Boehringer Ingelheim to test dual DLL3-targeting combination in small cell lung cancer.
Phase Ib/II study will evaluate obrixtamig, Boehringer DLL3/CD3 T-cell engager, with Zai Lab DLL3 antibody-drug conjugate zocilurtatug pelitecan.
Trial will enroll patients with extensive-stage small cell lung cancer plus poorly differentiated neuroendocrine carcinomas.
Zai Lab will supply zocilurtatug pelitecan, while Boehringer will sponsor trial, oversee day-to-day clinical operations.
Each company will retain rights to its respective assets under agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English